BriaCell Breast Cancer Survival Data: 13.3 Months Versus 7.2-9.8 Months
October 21 2020 - 5:30AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXF), a
clinical-stage biotechnology company specializing in targeted
immunotherapy for advanced breast cancer, announces the overall
survival (OS) data of its lead product candidate, Bria-IMT™, in
combination with Checkpoint Inhibitors in advanced breast cancer
patients. Additional overall survival data from the clinical
studies will be presented in a poster session on December 9 – 11
during the 2020 San Antonio Breast Cancer Symposium® (SABCS), a
virtual event.
Median OS of 13.3 months has been
observed in the Phase I/IIa study for patients treated
with Bria-IMT™ in combination with immune checkpoint
inhibitors in patients with advanced breast cancer (third line or
later). Further, median OS had reached 14 months in
patients with Grade I/II tumors. Checkpoint inhibitors included
pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.),
and more recently, Incyte’s INCMGA00012 (by Incyte Corporation).
This data is derived primarily from patients previously disclosed
(see press release dated June 22, 2020). An OS of 7.2-9.8 months in
similar patients with metastatic breast cancer in the third line
setting has recently been published (Kazmi S, et al. “Overall
survival analysis in patients with metastatic breast cancer and
liver or lung metastases treated with eribulin, gemcitabine, or
capecitabine.” Breast Cancer Res Treat. 2020).
The SABCS® poster
will also summarize the clinical
and pathological data of the Bria-IMT™ monotherapy
study and Phase I/IIa clinical study of Bria-IMT™ in combination
with immune checkpoint inhibitors including pembrolizumab, and more
recently, Incyte’s INCMGA00012, in advanced breast cancer with
grade I and grade II tumors.
The SABCS®
presentation will be posted on
https://briacell.com/novel-technology/scientific-publications/.
The details on the SABCS® poster presentation
are as follows:
Abstract
Number: 1313Presentation
Title: Response to a modified whole tumor cell
targeted immunotherapy in patients with advanced breast cancer
correlates with tumor gradeSession
Date: December 9-11,
2020Program Number: PS17-20Session
Title: Poster Session
17About BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer.
For additional information on BriaCell, please
visit: https://briacell.com/.
About SABCS®
Since its inception in 1977, San Antonio Breast
Cancer Symposium (SABCS®) has grown to a program that covers the
latest research on the experimental biology, etiology, prevention,
diagnosis, and treatment of breast cancer and premalignant breast
disease. The Symposium is attended by a large international
audience of researchers, health professionals, physicians,
oncologists, and those with a special interest in breast cancer
from over 90 countries.
To complement the clinical focus of the annual
SABCS®, Baylor College of Medicine became a joint sponsor of SABCS®
in 2005. Additionally, the Cancer Therapy & Research Center
(CTRC) at UT Health Science Center San Antonio and American
Association for Cancer Research (AACR), a prestigious scientific
organization known for its basic, translational and clinical cancer
research, began collaboration with SABC® in 2007. The Symposium was
renamed the CTRC-AACR San Antonio Breast Cancer Symposium.
For additional information on 2020 SABCS®,
please visit: https://www.sabcs.org.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact, this
news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation (also
known as "forward-looking statements") which are subject to known
and unknown risks relevant to the Company in particular and to the
biotechnology and pharmaceutical industries in general,
uncertainties and other factors that may cause actual events to
differ materially from current expectation. These risks are more
fully described in the Company's public filings available at
www.sedar.com.
These forward-looking statements include, but are
not limited to, BriaCell’s plans, objectives, expectations and
intentions. Such forward-looking statements reflect BriaCell's
current beliefs and are based on information currently available to
management. Although the forward-looking statements contained in
this news release are based upon what BriaCell believes are
reasonable assumptions, there can be no assurance that actual
results will be consistent with these forward-looking
statements.
Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date of this press release. The Company disclaims any intention or
obligation, except to the extent required by law, to update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please contact:
BriaCell Therapeutics
Corp.:William V. Williams, MDPresident & CEOPhone:
1-888-485-6340
BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Apr 2023 to Apr 2024